• norsk
    • English
  • norsk 
    • norsk
    • English
  • Logg inn
Vis innførsel 
  •   Hjem
  • University of Bergen Library
  • Registrations from Cristin
  • Vis innførsel
  •   Hjem
  • University of Bergen Library
  • Registrations from Cristin
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Elevated plasma cystathionine is associated with increased risk of mortality among patients with suspected or established coronary heart disease

Dhar, Indu; Lysne, Vegard; Svingen, Gard Frodahl Tveitevåg; Ueland, Per Magne; Gregory, Jesse F.; Bønaa, Kaare Harald; Nygård, Ottar
Journal article, Peer reviewed
Accepted version
Thumbnail
Åpne
Accepted Version (675.0Kb)
Permanent lenke
https://hdl.handle.net/11250/2738673
Utgivelsesdato
2019
Metadata
Vis full innførsel
Samlinger
  • Department of Clinical Science [1678]
  • Registrations from Cristin [5457]
Originalversjon
American Journal of Clinical Nutrition. 2019, 109, 6, 1546–1554   10.1093/ajcn/nqy391
Sammendrag
Background

Elevated circulating cystathionine levels are related to atherosclerotic cardiovascular disease, a leading cause of death globally.

Objective

We investigated whether plasma cystathionine was associated with mortality in patients with suspected or established coronary heart disease (CHD).

Methods

Data from 2 independent cohorts of patients with suspected stable angina pectoris (SAP) (3033 patients; median 10.7 y follow-up; 648 deaths) or acute myocardial infarction (AMI) (3670 patients; median 7.0 y follow-up; 758 deaths) were included. Hazard ratios with 95% CIs per SD increment of log-transformed cystathionine were calculated using Cox regression modeling. Endpoint data was obtained from a national health registry.

Results

Among patients with SAP, there was a positive association between plasma cystathionine and death (age- and sex-adjusted HRs [95% CI] per SD: 1.23 [1.14, 1.32], 1.29 [1.16, 1.44], and 1.17 [1.05, 1.29] for total, cardiovascular, and noncardiovascular mortality, respectively). Corresponding risk estimates were 1.28 (1.19, 1.37) for all-cause, 1.33 (1.22, 1.45) for cardiovascular, and 1.19 (1.06, 1.34) for noncardiovascular death among AMI patients. In both cohorts, estimates were slightly attenuated after multivariate adjustments for established CHD risk factors. Subgroup analyses showed that the relation between cystathionine and all-cause mortality in SAP patients was stronger among nonsmokers and those with lower plasma concentration of pyridoxal-5′-phosphate (P-interaction ≤ 0.01 for both).

Conclusions

Elevated plasma cystathionine is associated with both cardiovascular and noncardiovascular mortality among patients with suspected or established CHD. The joint risk associations of high plasma cystathionine with lifestyle factors and impaired vitamin B-6 status on mortality need further investigation. This trial was registered at clinicaltrials.gov as NCT00354081 and NCT00266487.
Utgiver
Oxford University Press
Tidsskrift
American Journal of Clinical Nutrition
Opphavsrett
Copyright American Society for Nutrition 2019. All rights reserved

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit
 

 

Bla i

Hele arkivetDelarkiv og samlingerUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifterDenne samlingenUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifter

Min side

Logg inn

Statistikk

Besøksstatistikk

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit